Nestle invests $42.5M in Pronutria

Pronutria Biosciences Inc. (Cambridge, Mass.) raised $42.5 million in a series D round from a sole new investor, the Nestle Health Science subsidiary of Nestle S.A. (SIX:NESN). Pronutria develops amino acid-based therapeutics to treat muscle, neurological and liver disorders.

This year, Pronutria plans to begin two proof-of-concept studies: one for PN107 to treat myopenia (muscle wasting), and another for an undisclosed neurology candidate. The company expects to start corresponding pivotal trials in 2017. PN107 is an orally ingested protein with an amino acid combination and physicochemical profile optimized for myopenia conditions. ...